CRISPR Therapeutics
610 Main Street
Cambridge
Massachusetts
02142
United States
Tel: 617-580-9212
Website: http://crisprtx.com/
Email: info@crisprtx.com
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene editing platform. CRISPR is a revolutionary technology that allows for precise, directed changes to genomic DNA. The Company’s multi-disciplinary team of world-class researchers and drug developers is working on a number of wholly-owned programs to treat serious diseases with high unmet need.
268 articles about CRISPR Therapeutics
-
CRISPR Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
11/10/2022
CRISPR Therapeutics today presented data for CTX130™ for the treatment of relapsed or refractory renal cell carcinoma (RCC) as an oral presentation delivered by City of Hope’s Sumanta Pal, M.D.
-
CRISPR Therapeutics Announces Poster Presentation on CTX110® at the American Society of Hematology (ASH) 2022 Annual Meeting
11/3/2022
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present a poster on CTX110®, its wholly-owned allogeneic CAR-T cell investigational therapy targeting CD19+ B-cell malignancies, at the American Society of Hematology (ASH) 2022 Annual Meeting, taking place December 10-13, 2022.
-
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
11/1/2022
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the third quarter ended September 30, 2022.
-
CRISPR Therapeutics Announces Planned Transition of Chief Operating Officer
10/27/2022
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer, Lawrence Klein, Ph.D., will be stepping down from the Company to pursue external opportunities.
-
While worthy advances have recently been made in sickle cell disease, companies such as Graphite Bio, bluebird bio, Vertex Pharmaceuticals and Editas Medicine have loftier ambitions.
-
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
10/5/2022
CRISPR Therapeutics today announced an oral presentation and a poster presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, taking place in Boston, MA or virtually from November 8 to 12, 2022.
-
The FDA had a busy week, approving drugs, greenlighting clinical trials and other regulatory activities for Immuneering, Amylyx, Sarepta, Sanofi, and Regeneron and more.
-
CRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy
9/29/2022
CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that members of its senior management team are scheduled to participate in the BMO Biopharma Spotlight Series: Gene Editing and Therapy on Thursday, October 6, 2022, at 9:00 a.m. ET.
-
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)
9/28/2022
CRISPR Therapeutics today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX130™, the Company’s wholly-owned allogeneic CAR T cell therapy targeting CD70, for the treatment of Mycosis Fungoides and Sézary Syndrome (MF/SS).
-
The FDA has granted a rolling review to CRISPR Therapeutics and Vertex's exa-cel, a potential one-time treatment for sickle cell disease and transfusion-dependent beta-thalassemia.
-
Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
9/27/2022
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that Vertex has concluded discussions with the U.S. Food and Drug Administration (FDA), and the FDA granted exagamglogene autotemcel (exa-cel) a rolling review for the potential treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
-
CRISPR Therapeutics to Participate in Upcoming Investor Conferences in September 2022
8/31/2022
CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that members of its senior management team are scheduled to participate in the following investor conferences in September.
-
CRISPR Therapeutics, Clovis Oncology and VistaGen all released Q2 results this week, while GreenLight Biosciences has some extra cash to work with.
-
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
8/8/2022
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the second quarter ended June 30, 2022.
-
Vertex Pharmaceuticals plans to acquire ViaCyte for $320 million in cash. ViaCyte focuses on stem cell-derived cell replacement therapies that they hope will cure type 1 diabetes (T1D).
-
Precision BioSciences and Novartis are teaming up to develop a potential cure for hemoglobinopathies such as sickle cell disease and beta-thalassemia.
-
CRISPR Therapeutics could be on the cusp of achieving a first in gene therapy, the first company to achieve regulatory approval for a CRISPR-Cas9 program.
-
Shares of CRISPR Therapeutics fell more than 11% on Monday as investors react negatively to the endorsement of a rival beta-thalassemia gene therapy developed by bluebird bio.
-
CRISPR Therapeutics shared positive initial data from its Phase I COBALT-LYM trial of CTX130 for cancer which demonstrated safety and efficacy when used to target CD70.
-
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress
6/11/2022
Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announce presentation of new data on exa-cel, formerly known as CTX001™, from CLIMB-111, CLIMB-121 and CLIMB-131 highlighting the potentially transformative profile of this investigational therapy for people with transfusion-dependent beta thalassemia or severe sickle cell disease and provided additional program updates.